Drug class
Antimetabolites clinical trials
A class of medicines: the studies that test any of its 95 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones.
Keep track of what changes. Save the antimetabolites studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesMedicines in this class
Studies that test each. A study of two counts under both, and once above.
- Trifluridine tipiracil drug combination
- 101
And 55 more, each tested in fewer studies.
Studies by the year they started
8,000 studies that test it; most in 2006 (374); 18 more planned to start later
| Year | Studies |
|---|---|
| 1990 | 7 |
| 1991 | 3 |
| 1992 | 2 |
| 1993 | 9 |
| 1994 | 14 |
| 1995 | 24 |
| 1996 | 26 |
| 1997 | 60 |
| 1998 | 93 |
| 1999 | 137 |
| 2000 | 136 |
| 2001 | 165 |
| 2002 | 208 |
| 2003 | 280 |
| 2004 | 307 |
| 2005 | 348 |
| 2006 | 374 |
| 2007 | 367 |
| 2008 | 328 |
| 2009 | 342 |
| 2010 | 294 |
| 2011 | 298 |
| 2012 | 306 |
| 2013 | 317 |
| 2014 | 283 |
| 2015 | 311 |
| 2016 | 290 |
| 2017 | 262 |
| 2018 | 283 |
| 2019 | 261 |
| 2020 | 311 |
| 2021 | 265 |
| 2022 | 261 |
| 2023 | 260 |
| 2024 | 268 |
| 2025 | 250 |
| 2026 | 250 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1,813 · Other 6,481
M.D. Anderson Cancer Center (333) · National Cancer Institute (NCI) (321) · National Institute of Allergy and Infectious Diseases (NIAID) (168) · Eli Lilly and Company (161) · Hoffmann-La Roche (156) · Memorial Sloan Kettering Cancer Center (123) · Fred Hutchinson Cancer Center (107) · Sun Yat-sen University (91)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten.
Testing one of them · 8,294
- Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA TrialNot yet recruitingPhase 2University of WashingtonNCT07332351Written as Gemcitabine
- Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood CancersNot yet recruitingPhase 2National Cancer Institute (NCI)NCT07524530Written as Fludarabine
- Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialRecruitingPhase 3National Cancer Institute (NCI)NCT06096844Written as Pemetrexed
- Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid MalignanciesRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06383572Written as Fludarabine phosphate
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract CancerRecruitingPhase 2/3National Cancer Institute (NCI)NCT04628767Written as Methotrexate
- Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersRecruitingPhase 1/2National Cancer Institute (NCI)NCT02830724Written as Fludarabine
- Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesRecruitingPhase 1National Cancer Institute (NCI)NCT06904066Written as fludarabine phosphate
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal CancerRecruitingPhase 2National Cancer Institute (NCI)NCT06029270Written as Gemcitabine
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05564390Written as Azacitidine
- Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05554393Written as Azacitidine
- Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05554406Written as Azacitidine
- Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)RecruitingPhase 2National Cancer Institute (NCI)NCT01419561Written as Zidovudine
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05564377Written as Fluorouracil
- TC-D101 Cell Therapy for Patients With DLL3-Positive SCLCRecruitingEarly Phase 1TCRCure Biopharma Ltd.NCT07246304Written as TC-D101 CAR-T
- DON in Pediatric Cerebral MalariaRecruitingPhase 1/2Douglas Postels, MD, MSNCT05478720Written as 6-diazo-5-oxo-L-norleucine (DON)
- Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel CancersRecruitingPhase 2SWOG Cancer Research NetworkNCT04205968Written as Fluorouracil
- Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver CancerRecruitingPhase 2Center Eugene MarquisNCT05265208Written as Capecitabine
- Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)RecruitingPhase 1/2Masonic Cancer Center, University of MinnesotaNCT07008638Written as CPX-351
- A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid LeukemiaRecruitingPhase 1National Cancer Institute (NCI)NCT07012044Written as Decitabine
- Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II TrialRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07847710Written as Gemcitabine & oxaliplatin
See all 8,294 studies that test one of the antimetabolites →